Alpine Immune Sciences, Inc.
ALPNNASDAQHealthcare
$64.97
+$0.01(+0.02%)
Market Cap$4.5B
P/E Ratio—
52W High$65.0
52W Low$8.33
Alpine Immune Sciences, Inc. (ALPN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ALPN · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $58.88M | $30.06M | $23.44M | $9.34M | $1.74M |
| Cost of Revenue | $80.90M | $0.60M | $0.62M | $27.18M | $35.85M |
| Gross Profit | ($22.03M) | $29.47M | $22.82M | ($17.85M) | ($34.11M) |
| Gross Margin %(computed) | -37.41% | 98.01% | 97.36% | -191.22% | — |
| Operating Expenses | |||||
| R&D Expenses | $80.90M | $70.24M | $58.74M | $27.18M | $35.85M |
| G&A Expenses | $22.22M | $17.97M | $14.56M | $10.90M | $9.47M |
| Total Operating Expenses | $103.13M | $88.21M | $73.30M | $38.08M | $45.31M |
| Operating Income | ($44.25M) | ($58.15M) | ($49.86M) | ($28.75M) | ($43.57M) |
| Operating Margin %(computed) | -75.16% | -193.41% | -212.68% | -307.97% | — |
| Interest Income | $11.85M | $3.29M | $0.26M | $0.24M | $1.25M |
| Interest Expense | $0.10M | $0.48M | $0.82M | $0.78M | $0.34M |
| Income Before Tax | ($32.08M) | ($55.43M) | ($50.42M) | ($27.95M) | ($41.85M) |
| Income Tax Expense | $0.10M | $2.33M | ($0.09M) | ($0.01M) | $0.68M |
| Net Income | ($32.18M) | ($57.76M) | ($50.33M) | ($27.94M) | ($42.53M) |
| Net Margin %(computed) | -54.66% | -192.13% | -214.70% | -299.30% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.64 | $-1.73 | $-1.98 | $-1.34 | $-2.32 |
| Wtd Avg Shares | 50.00M | 33.44M | 25.48M | 20.83M | 18.36M |
| EBITDA | ($31.41M) | ($51.77M) | ($49.35M) | ($25.59M) | ($39.45M) |
| EBITDA Margin %(computed) | -53.34% | -172.18% | -210.51% | -274.16% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Alpine Immune Sciences, Inc. data
About Alpine Immune Sciences, Inc. (ALPN) Income Statement
Alpine Immune Sciences, Inc. (ALPN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, ALPN reported revenue of $0.06B, gross profit of ($0.02B) (gross margin -37.41%), and net income of ($0.03B) — a net profit margin of -54.66%.
Frequently asked questions
ALPN · 4 questionsAlpine Immune Sciences, Inc. (ALPN) reported revenue of $0.06B for 2023, up 95.8% year-over-year.
ALPN revenueALPN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08